Prof Saul Faust, co-study leader at the University of Southampton and a consultant paediatrician, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”
Trending
- Center right wins but far right snaps at heels – DW – 05/20/2025
- Choose France Summit: Indonesia eyes new markets and strategy to navigade Trump's trade war
- Why these Met Gala moments stand out in history
- Dakota Johnson is wearing a translucent dress from Gucci in Cannes
- Frans upcyclingbedrijf Losanje wint Andam Fashion Innovation Award 2025
- Julia Ducournau’s ‘Titane’ Follow-Up Movie
- What do YOU want to know about fat jabs? Dr Zoe calls for readers to send in questions for Live Q&A
- Spike Lee’s ‘Highest 2 Lowest’ Cannes Premiere